Rat CD70 Protein (Cytokine)

Cd70 molecule Protein Datasheet

CD70 Protein Product Information

• Synonym: CD70
• Protein Construction: A DNA sequence encoding the rat CD70(D3ZGU3) (Gln46-Pro195) was expressed, fused with Fc region of human IgG1 at the N-terminus.
• Source: Rat
• Expression Host: Human Cells

CD70 Protein QC Testing

• Purity: > 95 % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Glu
• Molecular Mass: The recombinant rat CD70 comprises 410 amino acids and predicts a molecular mass of 45 kDa. The apparent molecular mass of the recombinant protein is approximately 55 kDa in SDS-PAGE under reducing conditions due to glycosylation.
• Formulation: Lyophilized from sterile PBS, pH7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: CD70 protein

CD70 Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CD70 Protein Description

CD70, also known as CD27 ligand (CD70 / CD27L / TNFSF7), is a member of the tumor necrosis factor superfamily (ie. TNFSF7) and a surface antigen found on activated T-and B-lymphocytes and mature dendritic cells. CD70 is a single-pass type Ⅲ transmebrane glycoprotin consisting of a short cytoplasmic domain (1-17aa) , a transmembrane domain (18-38 aa) and a 155aa extracellular domain (39-193), and exists as a homotrimer in vivo. Binding of CD70 to its receptor CD27 induces in priming, effector functions, differentiation and memory formation of T-cells, and thus is invloved in the biological processes including T-cell activation, the proliferation of costimulated T-cells, as well as the generation of cytolytic T-cells. CD70 expression on malignant cells coupled with its highly restricted expression on normal cells makes CD70 an attractive target for monoclonal antibody -based therapies.

References

1. Goodwin RG. et al., 1993, Cell. 73: 447-56.
2. Boursalian TE. et al., 2009, Adv Exp Med Biol. 647: 108-19.
3. Bowman MR. et al., 1994, J Immunol. 152: 1756-61.
4. McEarchern JA. et al., 2008, Clin Cancer Res. 14 (23): 7763-72.
5. Tesselaar K. et al., 2002, J Immunol. 169: 33-40.